Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Osteoarthritic Pain

This study has been completed.
Information provided by:
Mundipharma Pte Ltd. Identifier:
First received: June 27, 2006
Last updated: April 11, 2008
Last verified: April 2008

The primary objective of this study is to evaluate the efficacy and safety of BTDS compared to placebo in subjects with moderate to severe osteoarthritic pain of the hip or knee.

Condition Intervention Phase
Drug: Placebo
Drug: Buprenorphine Transdermal System
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Determine the Efficacy and Safety of BTDS Compared to Placebo in Subjects With Moderate to Severe Osteoarthritic Pain of the Hip or Knee

Resource links provided by NLM:

Further study details as provided by Mundipharma Pte Ltd.:

Primary Outcome Measures:
  • The time to the development of inadequate analgesia [ Time Frame: Up to 12weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percentage of subjects who developed inadequate analgesia, 'Average pain over the last 24 hours' scores [ Time Frame: 12weeks ] [ Designated as safety issue: No ]

Enrollment: 262
Study Start Date: May 2006
Study Completion Date: August 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 0 Drug: Placebo
Corresponding placebo is applied for 12weeks
Experimental: 1 Drug: Buprenorphine Transdermal System
Buprenorphine Transdermal System 5, 10 or 20mg/patch is applied for 12weeks

Detailed Description:

The primary objective of this study is to evaluate the efficacy and safety of buprenorphine transdermal system (BTDS) compared to placebo in subjects with moderate to severe osteoarthritic pain of the hip or knee who have a sub-optimal response to their non-opioid analgesic treatment and require opioid analgesics for pain control.


Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females ages 40 years or older.
  • Clinical diagnosis of osteoarthritis (OA) of the hip or knee.

Exclusion Criteria:

  • Subjects who have a current or past history of chronic disease(s), in addition to OA, requiring frequent analgesic therapy (e.g. headache, fibromyalgia, gout, rheumatoid arthritis, low back pain, and diabetic neuropathy).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00345787

Investigational Site
Nagoya, Aichi, Japan
Investigational Site
Okazaki, Aichi, Japan
Investigational Site
Ichikawa, Chiba, Japan
Investigational Site
Matsudo, Chiba, Japan
Investigational Site
Nagareyama, Chiba, Japan
Investigational Site
Annaka, Gunma, Japan
Investigational Site
Takasaki, Gunma, Japan
Investigational Site
Chitose, Hokkaido, Japan
Investigational Site
Sapporo, Hokkaido, Japan
Investigational Site
Kako, Hyogo, Japan
Investigational Site
Kobe, Hyogo, Japan
Investigational Site
Yokohama, Kanagawa, Japan
Investigational Site
Joyo, Kyoto, Japan
Investigational Site
Sendai, Miyagi, Japan
Investigational Site
Isahaya, Nagasaki, Japan
Investigational Site
Kasukabe, Saitama, Japan
Investigational Site
Koshigaya, Saitama, Japan
Investigational Site
Hikone, Shiga, Japan
Investigational Site
Adachi, Tokyo, Japan
Investigational Site
Arakawa, Tokyo, Japan
Investigational Site
Edogawa, Tokyo, Japan
Investigational Site
Koto, Tokyo, Japan
Investigational Site
Setagaya, Tokyo, Japan
Investigational Site
Suginami, Tokyo, Japan
Investigational Site
Himi, Toyama, Japan
Investigational Site
Kurobe, Toyama, Japan
Investigational Site
Fukui, Japan
Investigational Site
Osaka, Japan
Sponsors and Collaborators
Mundipharma K.K.
Study Chair: Mutsukuni Kataoka Department Head, Clinical Trial Operations, Clinical Development, Mundipharma K.K.
  More Information

No publications provided

Responsible Party: Mutsukuni Kataoka, Mundipharma K.K. Identifier: NCT00345787     History of Changes
Other Study ID Numbers: BUP3801
Study First Received: June 27, 2006
Last Updated: April 11, 2008
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Mundipharma Pte Ltd.:
Osteoarthritic Pain

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Analgesics, Opioid
Central Nervous System Agents
Central Nervous System Depressants
Narcotic Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 25, 2014